| Ident. | Authors (with country if any) | Title |
|---|
| 000070 (2016) |
K. Dujardin [France] ; N. Auzou [France] ; E. Lhommée [France] ; V. Czernecki [France] ; B. Dubois [France] ; A. Fradet [France] ; D. Maltete [France] ; M. Meyer [France] ; F. Pineau [France] ; E. Schmitt [France] ; F. Sellal [France] ; F. Tison [France] ; T. Vidal [France] ; J-P Azulay [France] ; M-L Welter [France] ; J-C Corvol [France] ; F. Durif [France] ; O. Rascol [France] | French consensus procedure for assessing cognitive function in Parkinson's disease. |
| 000279 (2015) |
A. Antonini [Italie] ; L. Bauer [Allemagne] ; E. Dohin [France] ; W H Oertel [Allemagne] ; O. Rascol [France] ; H. Reichmann [Allemagne] ; M. Schmid [Allemagne] ; P. Singh [Allemagne] ; E. Tolosa [Espagne] ; K Ray Chaudhuri [Royaume-Uni] | Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. |
| 000286 (2015) |
K Ray Chaudhuri [Royaume-Uni] ; A. Rizos [Royaume-Uni] ; C. Trenkwalder [Allemagne] ; O. Rascol [France] ; S. Pal [Royaume-Uni] ; D. Martino [Royaume-Uni] ; C. Carroll [Royaume-Uni] ; D. Paviour [Royaume-Uni] ; C. Falup-Pecurariu [Roumanie] ; B. Kessel [Royaume-Uni] ; M. Silverdale [Royaume-Uni] ; A. Todorova [Royaume-Uni] ; A. Sauerbier [Royaume-Uni] ; P. Odin [Suède] ; A. Antonini [Italie] ; P. Martinez-Martin [Espagne] | King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. |
| 000291 (2015) |
P. Odin [Allemagne] ; K. Ray Chaudhuri [Royaume-Uni] ; J T Slevin [États-Unis] ; J. Volkmann [Allemagne] ; E. Dietrichs [Norvège] ; P. Martinez-Martin [Espagne] ; J K Krauss [Allemagne] ; T. Henriksen [Danemark] ; R. Katzenschlager [Autriche] ; A. Antonini [Italie] ; O. Rascol [France] ; W. Poewe [Autriche] | Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. |
| 000692 (2013) |
P. Péran [France] ; F. Nemmi ; D. Méligne ; D. Cardebat ; A. Peppe ; O. Rascol ; C. Caltagirone ; J F Demonet ; U. Sabatini | Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: a fMRI study. |
| 000842 (2012) |
O. Rascol [France] ; J. Bronzova ; R A Hauser ; A E Lang ; C. Sampaio ; A. Theeuwes ; S V Van De Witte | Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. |
| 000865 (2012) |
S. Perez-Lloret [France] ; L. Nègre-Pagès ; A. Ojero-Senard ; P. Damier ; A. Destée ; F. Tison ; M. Merello ; O. Rascol | Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort. |
| 000951 (2011) |
O. Rascol [France] | Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release. |
| 000A14 (2010) |
P. Payoux [France] ; C. Brefel-Courbon ; F. Ory-Magne ; W. Regragui ; C. Thalamas ; S. Balduyck ; F. Durif ; J P Azulay ; F. Tison ; O. Blin ; J P Esquerre ; O. Rascol | Motor activation in multiple system atrophy and Parkinson disease: a PET study. |
| 000D12 (2007) |
A. Gerdelat-Mas [France] ; M. Simonetta-Moreau ; C. Thalamas ; F. Ory-Magne ; T. Slaoui ; O. Rascol ; C. Brefel-Courbon | Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. |
| 000F19 (????) |
O. Rascol [France] ; D J Brooks ; E. Melamed ; W. Oertel ; W. Poewe ; F. Stocchi ; E. Tolosa | Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. |
| 000F81 (2004) |
P. Pollak [France] ; F. Tison ; O. Rascol ; A. Destée ; J J Péré ; J M Senard ; F. Durif ; I. Bourdeix | Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. |
| 000F96 (2004) |
F. Durif [France] ; B. Debilly ; M. Galitzky ; D. Morand ; F. Viallet ; M. Borg ; S. Thobois ; E. Broussolle ; O. Rascol | Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. |
| 001104 (2003) |
P. Cintas [France] ; M. Simonetta-Moreau ; F. Ory ; C. Brefel-Courbon ; N. Fabre ; P. Chaynes ; J. Sabatier ; J C Sol ; O. Rascol ; I. Berry ; Y. Lazorthes | Deep brain stimulation for parkinson's disease: correlation between intraoperative subthalamic nucleus neurophysiology and most effective contacts. |
| 001108 (2002) |
Y. Tsuboi [États-Unis] ; M. Baker ; M L Hutton ; R J Uitti ; O. Rascol ; M-B Delisle ; X. Soulages ; J R Murrell ; B. Ghetti ; M. Yasuda ; O. Komure ; S. Kuno ; K. Arima ; N. Sunohara ; T. Kobayashi ; Y. Mizuno ; Z K Wszolek | Clinical and genetic studies of families with the tau N279K mutation (FTDP-17). |
| 001113 (2002) |
O. Rascol [France] ; J J Ferreira ; P. Payoux ; Ch Brefel-Courbon ; J L Montastruc | [Management of levodopa-induced dyskinesia]. |
| 001124 (2002) |
O. Rascol [France] ; P. Payoux ; J. Ferreira ; C. Brefel-Courbon | The management of patients with early Parkinson's disease. |
| 001128 (2002) |
M. Simonetta Moreau [France] ; S. Meunier ; M. Vidailhet ; S. Pol ; M. Galitzky ; O. Rascol | Transmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson's disease. |
| 001190 (2001) |
O. Rascol [France] ; J. Ferreira ; J L Montastruc | [Abnormal diurnal somnolence, "sleep attacks" and antiparkinson drugs]. |
| 001194 (2001) |
F. Chollet [France] ; I. Loubinoux ; J. Pariente ; C. Carel ; J F Albucher ; O. Rascol ; B. Guiraud-Chaumeil | [Pharmacologic modification of cerebral activity: value of functional neuroimaging]. |
| 001200 (2001) |
O. Rascol [France] ; I. Arnulf ; H. Peyro-Saint Paul ; C. Brefel-Courbon ; M. Vidailhet ; C. Thalamas ; A M Bonnet ; S. Descombes ; B. Bejjani ; N. Fabre ; J L Montastruc ; Y. Agid | Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. |
